JPH0124136B2 - - Google Patents
Info
- Publication number
- JPH0124136B2 JPH0124136B2 JP61243656A JP24365686A JPH0124136B2 JP H0124136 B2 JPH0124136 B2 JP H0124136B2 JP 61243656 A JP61243656 A JP 61243656A JP 24365686 A JP24365686 A JP 24365686A JP H0124136 B2 JPH0124136 B2 JP H0124136B2
- Authority
- JP
- Japan
- Prior art keywords
- water
- skin
- bacteria
- ppm
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 238000011282 treatment Methods 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 21
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 239000001301 oxygen Substances 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 230000001717 pathogenic effect Effects 0.000 claims description 13
- 229910052709 silver Inorganic materials 0.000 claims description 11
- 244000052616 bacterial pathogen Species 0.000 claims description 9
- 150000002500 ions Chemical class 0.000 description 37
- 210000003491 skin Anatomy 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 21
- 210000000170 cell membrane Anatomy 0.000 description 18
- 210000004379 membrane Anatomy 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 239000004332 silver Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 210000004102 animal cell Anatomy 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 201000001245 periodontitis Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- -1 Silver ions Chemical class 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 206010017711 Gangrene Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 201000004647 tinea pedis Diseases 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000025309 Hair disease Diseases 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940072172 tetracycline antibiotic Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 108010079292 betaglycan Proteins 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000003796 chancre Diseases 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000000461 effect on ribosome Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 210000000455 fourth toe Anatomy 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000008689 nuclear function Effects 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002459 polyene antibiotic agent Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61243656A JPS6396130A (ja) | 1986-10-14 | 1986-10-14 | 病原菌性皮膚および外腔粘膜疾患用治療水 |
| EP87305270A EP0254413A3 (en) | 1986-06-13 | 1987-06-12 | Silver-ionic water and its uses |
| KR870009489A KR880002754A (ko) | 1986-08-29 | 1987-08-29 | 온이온수 및 그의 용도 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61243656A JPS6396130A (ja) | 1986-10-14 | 1986-10-14 | 病原菌性皮膚および外腔粘膜疾患用治療水 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6396130A JPS6396130A (ja) | 1988-04-27 |
| JPH0124136B2 true JPH0124136B2 (ru) | 1989-05-10 |
Family
ID=17107056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61243656A Granted JPS6396130A (ja) | 1986-06-13 | 1986-10-14 | 病原菌性皮膚および外腔粘膜疾患用治療水 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6396130A (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014200778A (ja) * | 2013-04-10 | 2014-10-27 | 至明 松尾 | 抗酸化飲料水 |
| CN110972590B (zh) * | 2019-10-12 | 2021-04-20 | 浙江大学 | 一种利用低温等离子技术实现土壤推进式原位固氮的方法及装置 |
| CN111661854B (zh) * | 2020-05-08 | 2021-04-20 | 浙江大学 | 一种基于低温等离子体催化固氮的氮氧化物吸收利用系统 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376764A (en) * | 1981-08-10 | 1983-03-15 | Basf Wyandotte Corporation | Silver ion gel compositions |
| JPS6061529A (ja) * | 1983-09-07 | 1985-04-09 | グイレーモ・エム・ヴエレツツ | 皮膚外傷治療用組成物及びその治療方法 |
-
1986
- 1986-10-14 JP JP61243656A patent/JPS6396130A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376764A (en) * | 1981-08-10 | 1983-03-15 | Basf Wyandotte Corporation | Silver ion gel compositions |
| JPS6061529A (ja) * | 1983-09-07 | 1985-04-09 | グイレーモ・エム・ヴエレツツ | 皮膚外傷治療用組成物及びその治療方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6396130A (ja) | 1988-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Di Paolo et al. | Ozone therapy | |
| EP2200441B1 (en) | Composition and method for the prevention of oral disease | |
| US5334383A (en) | Electrically hydrolyzed salines as in vivo microbicides for treatment of cardiomyopathy and multiple sclerosis | |
| ES2701153T3 (es) | Método para tratar úlceras de piel utilizando una solución con agua de potencial reductivo oxidativo | |
| US6426066B1 (en) | Use of physiologically balanced, ionized, acidic solution in wound healing | |
| US8632823B2 (en) | Treatment of infected tissues with hypochlorous acid | |
| US20030147937A1 (en) | Use of compatible solutes as substances having free radical scavenging properties | |
| JP2006505516A (ja) | 生理学的にバランスのとれたイオン化された酸性溶液、および創傷治癒における使用方法 | |
| US20080020025A1 (en) | Composition for wound care and method of using same | |
| CN101163491B (zh) | 利用氧化还原电位水溶液治疗皮肤溃疡的方法 | |
| WO2007070637A2 (en) | Method of treating open wounds using hypochlorous acid | |
| JP5434915B2 (ja) | ヘリコバクターピロリ菌の駆除剤 | |
| JPH0124136B2 (ru) | ||
| Harris et al. | The Development and Evaluation of Melatonin-Loaded, Calcium Oxide Nanoparticle-Based Neem and Clove Extract: An In Vitro Study | |
| WO1995014484A1 (fr) | GENERATEUR DE RADICAUX LIBRES $i(IN VIVO) | |
| Abbott | Treatment of warts with bleomycin | |
| DE602004011786T2 (de) | Taurin bromamin für die inhibierung von pathogenen bakterien und pilzwachstum sowie in einer mikrobiziden zusammensetzung | |
| US6932966B1 (en) | Topically applied reconstituted ocean water mixture and method of producing and using the mixture | |
| JPH0124134B2 (ru) | ||
| RU2306939C1 (ru) | Способ лечения фурункулеза | |
| Rakovsky et al. | Application of ozone in medicine | |
| CA2299205A1 (en) | Super-oxygenated water solutions and methods of use | |
| JP2004518758A (ja) | 亜セレン酸塩またはセレン酸塩を含有する製剤の使用 | |
| RU2266757C2 (ru) | Способ подавления коронавируса атипичной пневмонии | |
| US20180110803A1 (en) | Neutral Electrolyzed Water and Uses Thereof |